Leerink cuts Immunovant stock price target on failed TED trial By Investing.com

Phase 3 trials of batoclimab failed to meet the primary proptosis responder endpoint at Week 24, representing a material clinical setback. Leerink trimmed its price target to $50 from $52 but kept an Outperform rating; Oppenheimer reiterated Outperform with a $54 target while Bernstein initiated Market Perform at $28, and analyst targets range roughly $22–$57. Immunovant reported Q3 2026 EPS of -$0.61 vs a -$0.72 forecast (a positive surprise), the stock trades at $24.70 and is up ~53% over the past year, and management/analysts are focusing on next‑generation IMVT‑1402 with multiple near‑term readouts expected across 2026–2027.

Analysis

The market reaction has reset IMVT from growth-to-readout to platform/optional-ity valuation; that typically compresses near-term liquidity and amplifies implied-volatility skew around any non-binary next-gen program updates. Funds that previously held the name for momentum will rotate out, leaving a higher concentration of event-driven and long-biotech holders; that creates asymmetric trading opportunities where premium can be sold into temporary fear while maintaining optional upside.

Second-order competitive dynamics favor well-capitalized partners and CDMO networks: companies with modest clinical setbacks lose bargaining leverage for late-stage manufacturing and co-development terms, making strategic partnerships or bolt-on M&A more likely than solitary re-runs of late pivotal programs. For acquirers, a differentiated next-gen FcRn or platform asset can be priced as a takeover option rather than a standalone commercial franchise, compressing public multiples but increasing strategic takeover premiums for successful readouts.

The dominant risks are execution (trial design/endpoint tweaks), dilution if management leverages the equity window, and IV repricing around each discrete readout or partnering announcement. A practical reversal requires either a clear mechanistic signal from a non-pivotal cohort or a partnering deal that de-risks commercialization; absent that, expect a drawn-out, higher-volatility path until one of those catalysts materializes.

Key Decisions for Investors

• Buy a structured long: IMVT long-dated (12–18 month) call spread financed by selling nearer-term calls (ticker: IMVT). Aim for a 2–3x upside if a positive next-gen readout/partnership occurs; max loss = net premium paid, cap upside reduces cost and hedges IV collapse.
• Premium sell + hedge: Sell short-dated IMVT puts (1–3 month, ~25-delta) to collect premium and buy inexpensive long-dated OTM puts as tail protection. If shares gap down, roll into longer-dated protection; this strategy generates yield while limiting catastrophic downside.
• Event pair: Long IMVT equity size vs short biotech ETF (ticker: XBI) to isolate idiosyncratic recovery. Use modest leverage (1:1 ratio) with stop at 30% drawdown on the pair; target asymmetric payoff if IMVT’s platform narrative is restored while sector re-rates lower.
• Catalyst arb: Accumulate small equity position ahead of partnering windows and use OTM calls to punch up exposure; if a partnering announcement arrives, trim into strength. Position sizing should cap equity exposure to <2% of portfolio to control dilution and trial risk.